X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1946) 1946
Book Review (752) 752
Publication (91) 91
Book Chapter (22) 22
Newspaper Article (5) 5
Newsletter (4) 4
Dissertation (3) 3
Magazine Article (3) 3
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1474) 1474
humans (1242) 1242
diabetes mellitus, type 2 - drug therapy (973) 973
type 2 diabetes (883) 883
diabetes (744) 744
dipeptidyl-peptidase iv inhibitors - therapeutic use (629) 629
endocrinology & metabolism (629) 629
hypoglycemic agents - therapeutic use (608) 608
male (530) 530
glucagon-like peptide-1 (443) 443
animals (420) 420
pharmacology & pharmacy (412) 412
female (404) 404
glucose (401) 401
sitagliptin (394) 394
diabetes mellitus (383) 383
dipeptidyl peptidase-4 inhibitor (383) 383
double-blind (363) 363
middle aged (330) 330
hypoglycemic agents (328) 328
dipeptidyl peptidase-4 inhibitors (327) 327
treatment outcome (315) 315
dipeptidyl-peptidase iv inhibitors - pharmacology (310) 310
glycemic control (306) 306
aged (301) 301
drug therapy (298) 298
risk factors (289) 289
type-2 diabetes-mellitus (288) 288
type 2 diabetes mellitus (282) 282
metformin (280) 280
dipeptidyl-peptidase iv inhibitors - adverse effects (268) 268
hypoglycemic agents - adverse effects (267) 267
insulin (262) 262
diabetes mellitus, type 2 - blood (256) 256
analysis (254) 254
safety (248) 248
care and treatment (245) 245
dpp-4 inhibitors (241) 241
internal medicine (236) 236
dpp-4 inhibitor (232) 232
diabetes mellitus, type 2 - complications (230) 230
diabetes therapy (227) 227
clinical trials (215) 215
cardiac & cardiovascular systems (214) 214
medicine & public health (214) 214
dextrose (203) 203
hypoglycemic agents - pharmacology (203) 203
alogliptin (201) 201
blood glucose - metabolism (201) 201
vildagliptin (200) 200
heart failure (198) 198
dipeptidyl peptidase 4 - metabolism (197) 197
blood glucose - drug effects (196) 196
glucagon (196) 196
efficacy (195) 195
research (194) 194
uracil - analogs & derivatives (192) 192
mortality (191) 191
hypoglycemic agents - administration & dosage (183) 183
adult (182) 182
drug therapy, combination (180) 180
peptidase (180) 180
linagliptin (175) 175
cardiovascular disease (172) 172
cardiovascular outcomes (170) 170
inhibitors (166) 166
studies (161) 161
mellitus (160) 160
heart-failure (158) 158
improves glycemic control (158) 158
risk (155) 155
hypoglycemia (153) 153
cardiovascular diseases (152) 152
health aspects (152) 152
review (152) 152
patients (151) 151
beta-cell function (150) 150
hyperglycemia (150) 150
mice (147) 147
adamantane - analogs & derivatives (146) 146
glp-1 (144) 144
peptides (143) 143
saxagliptin (141) 141
dipeptidyl-peptidase iv inhibitors - administration & dosage (139) 139
insulin resistance (136) 136
medical research (131) 131
medicine, general & internal (130) 130
glycated hemoglobin a - metabolism (126) 126
randomized controlled trials as topic (126) 126
rats (126) 126
diabetes mellitus, type 2 - metabolism (125) 125
drugs (118) 118
piperidines - therapeutic use (118) 118
chemistry, medicinal (116) 116
cardiology (115) 115
therapy (115) 115
glycosylated hemoglobin (114) 114
pharmacokinetics (114) 114
uracil - therapeutic use (114) 114
endocrinology (110) 110
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1948) 1948
French (7) 7
Japanese (6) 6
German (5) 5
Korean (3) 3
Chinese (1) 1
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 01/2016, Volume 39, Issue 1, pp. 139 - 148
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2007, Volume 50, Issue 10, pp. 2297 - 2300
Journal Article
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 08/2011, Volume 58, Issue 2, pp. 157 - 166
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9982, pp. 2067 - 2076
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 668 - 673
Aim As there have been concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk, we evaluated the cardiovascular profile... 
cardiovascular disease | type 2 diabetes | DPP‐IV | inhibitor | Type 2 diabetes | Cardiovascular disease | DPP-IV inhibitor | METFORMIN | MONOTHERAPY | GLP-1 | EFFICACY | INADEQUATE GLYCEMIC CONTROL | PIOGLITAZONE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | THERAPIES | OUTCOMES | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Diabetic Cardiomyopathies - physiopathology | Incidence | Cardiovascular Diseases - complications | Diabetic Angiopathies - physiopathology | Cardiovascular Diseases - epidemiology | Female | Diabetes Mellitus, Type 2 - complications | Severity of Illness Index | Diabetic Angiopathies - chemically induced | Cardiovascular Diseases - physiopathology | Double-Blind Method | Proportional Hazards Models | Uracil - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Diabetic Cardiomyopathies - epidemiology | Piperidines - adverse effects | Diabetic Angiopathies - epidemiology | Aged | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Cardiomyopathies - chemically induced | Cohort Studies | Uracil - analogs & derivatives | Hypoglycemic agents | Safety and security measures | Analysis | Heart attack | Confidence intervals | Medical research | Heart attacks | Diabetes | Index Medicus
Journal Article